chr2-214780756-C-T

Variant names:

• chr2-214780756-C-T
• rs568305044
• NM_000465.4:c.1118G>A

Variant summary

Our verdict is Uncertain significance. The variant received 1 ACMG points: 4P and 3B. PM1 PM2 BP4_Moderate BP6

The NM_000465.4(BARD1):​c.1118G>A​(p.Gly373Asp) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000137 in 1,461,782 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 17/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G373S) has been classified as Uncertain significance.

• Frequency:
  • Genomes: not found (cov: 33)
  • Exomes 𝑓: 0.0000014 (0 hom.)
• Consequence: BARD1 NM_000465.4 missense
• Clinical Significance: Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:2 B:1
• Conservation: PhyloP100: -0.411
• Publications: 2 publications found

Genes affected

BARD1 (HGNC:952): (BRCA1 associated RING domain 1) This gene encodes a protein which interacts with the N-terminal region of BRCA1. In addition to its ability to bind BRCA1 in vivo and in vitro, it shares homology with the 2 most conserved regions of BRCA1: the N-terminal RING motif and the C-terminal BRCT domain. The RING motif is a cysteine-rich sequence found in a variety of proteins that regulate cell growth, including the products of tumor suppressor genes and dominant protooncogenes. This protein also contains 3 tandem ankyrin repeats. The BARD1/BRCA1 interaction is disrupted by tumorigenic amino acid substitutions in BRCA1, implying that the formation of a stable complex between these proteins may be an essential aspect of BRCA1 tumor suppression. This protein may be the target of oncogenic mutations in breast or ovarian cancer. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2013]

BARD1 Gene-Disease associations (from GenCC):

• breast cancer

  Inheritance: AD Classification: DEFINITIVE Submitted by: G2P
• hereditary breast carcinoma

  Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae), ClinGen
• familial ovarian cancer

  Inheritance: AD Classification: LIMITED Submitted by: ClinGen
• hereditary nonpolyposis colon cancer

  Inheritance: AD Classification: LIMITED Submitted by: ClinGen

ACMG classification

Our verdict: Uncertain_significance. The variant received 1 ACMG points.

• PM1: In a hotspot region, there are 2 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 8 benign, 36 uncertain in NM_000465.4
• PM2: Very rare variant in population databases, with high coverage
• BP4: Computational evidence support a benign effect (MetaRNN=0.07544458).
• BP6: Variant 2-214780756-C-T is Benign according to our data. Variant chr2-214780756-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 460689. Variant chr2-214780756-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 460689. Variant chr2-214780756-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 460689. Variant chr2-214780756-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 460689. Variant chr2-214780756-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 460689. Variant chr2-214780756-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 460689. Variant chr2-214780756-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 460689. Variant chr2-214780756-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 460689. Variant chr2-214780756-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 460689. Variant chr2-214780756-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 460689. Variant chr2-214780756-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 460689. Variant chr2-214780756-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 460689. Variant chr2-214780756-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 460689. Variant chr2-214780756-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 460689. Variant chr2-214780756-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 460689. Variant chr2-214780756-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 460689. Variant chr2-214780756-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 460689.

Transcripts

RefSeq

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	MANE	Protein	UniProt
BARD1	NM_000465.4	c.1118G>A	p.Gly373Asp	missense_variant	Exon 4 of 11	ENST00000260947.9	NP_000456.2

Ensembl

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	TSL	MANE	Protein	Appris	UniProt
BARD1	ENST00000260947.9	c.1118G>A	p.Gly373Asp	missense_variant	Exon 4 of 11	1	NM_000465.4	ENSP00000260947.4

Frequencies

GnomAD3 genomes Cov.: 33

GnomAD4 exome AF: 0.00000137 AC: 2 AN: 1461782 Hom.: 0 Cov.: 35 AF XY: 0.00000138 AC XY: 1 AN XY: 727188

⚠️ The allele balance in gnomAD version 4 Exomes is significantly skewed from the expected value of 0.5.

African (AFR) AF: 0.0000299 AC: 1 AN: 33480

American (AMR) AF: 0.00 AC: 0 AN: 44706

Ashkenazi Jewish (ASJ) AF: 0.0000383 AC: 1 AN: 26132

East Asian (EAS) AF: 0.00 AC: 0 AN: 39690

South Asian (SAS) AF: 0.00 AC: 0 AN: 86256

European-Finnish (FIN) AF: 0.00 AC: 0 AN: 53412

Middle Eastern (MID) AF: 0.00 AC: 0 AN: 5768

European-Non Finnish (NFE) AF: 0.00 AC: 0 AN: 1111954

Other (OTH) AF: 0.00 AC: 0 AN: 60384

⚠️ The allele balance in gnomAD4 Exomes is highly skewed from 0.5 (p-value = 0.029673), which strongly suggests a high chance of mosaicism in these individuals.

GnomAD4 genome Cov.: 33

Alfa AF: 0.00 Hom.: 0

Asia WGS AF: 0.000577 AC: 2 AN: 3478

ClinVar

Significance: Conflicting classifications of pathogenicity

Submissions summary: Uncertain:2 Benign:1

Revision: criteria provided, conflicting classifications

Submissions by phenotype

Familial cancer of breast Uncertain:1

Aug 19, 2023

Labcorp Genetics (formerly Invitae), Labcorp

Significance: Uncertain significance

Review Status: criteria provided, single submitter

Collection Method: clinical testing

In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Not Available"; PolyPhen-2: "Benign"; Align-GVGD: "Not Available". The aspartic acid amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. ClinVar contains an entry for this variant (Variation ID: 460689). This variant has not been reported in the literature in individuals affected with BARD1-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces glycine, which is neutral and non-polar, with aspartic acid, which is acidic and polar, at codon 373 of the BARD1 protein (p.Gly373Asp). -

Hereditary breast ovarian cancer syndrome Uncertain:1

Apr 19, 2022

National Health Laboratory Service, Universitas Academic Hospital and University of the Free State

Significance: Uncertain significance

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

Hereditary cancer-predisposing syndrome Benign:1

Jan 09, 2024

Ambry Genetics

Significance: Likely benign

Review Status: criteria provided, single submitter

Collection Method: clinical testing

This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Computational scores

Source: dbNSFP v4.3

Name	Calibrated prediction	Score	Prediction
AlphaMissense	Benign	0.073
BayesDel_addAF	Benign	-0.24	T
BayesDel_noAF	Benign	-0.59
CADD	Benign	0.16
DANN	Benign	0.17
DEOGEN2	Benign	0.066	T;.
Eigen	Benign	-1.6
Eigen_PC	Benign	-1.6
FATHMM_MKL	Benign	0.021	N
LIST_S2	Benign	0.38	T;T
M_CAP	Benign	0.020	T
MetaRNN	Benign	0.075	T;T
MetaSVM	Benign	-0.99	T
MutationAssessor	Benign	0.26	N;.
PhyloP100		-0.41
PrimateAI	Benign	0.22	T
PROVEAN	Benign	0.43	N;.
REVEL	Benign	0.059
Sift	Benign	0.56	T;.
Sift4G	Benign	0.53	T;T
Polyphen		0.0	B;.
Vest4		0.11
MutPred		0.47		Loss of MoRF binding (P = 0.0567);.;
MVP		0.51
MPC		0.098
ClinPred		0.022	T
GERP RS		-3.3
Varity_R		0.032
gMVP		0.15
Mutation Taster		=96/4	polymorphism

Splicing

Name	Calibrated prediction	Score	Prediction
SpliceAI score (max)		0.0		Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Other links and lift over

dbSNP: rs568305044; hg19: chr2-215645480;